Skip to content

Effectiveness and Cost-effectiveness of VTE Prevention Strategies in Gynecological Surgery

Cost-Effectiveness Analysis of Perioperative Venous Thromboembolism Prevention Strategies in Gynecology Based on Modified Caprini Score: A Retrospective Nested Case-Control Study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07455253
Enrollment
234
Registered
2026-03-06
Start date
2025-11-10
Completion date
2026-08-15
Last updated
2026-03-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Deep Vein Thrombosis (DVT), Gynecological Surgery, Pulmonary Embolism (PE), Venous Thromboembolism

Keywords

Cost-Effectiveness, Prevention, Retrospective Study, Health Economics

Brief summary

Venous thromboembolism (VTE) is a highly preventable but potentially fatal complication following gynecological surgery. The Caprini risk assessment model is widely used, but real-world evidence evaluating the net clinical benefit and cost-effectiveness of different prophylaxis strategies (mechanical vs. pharmacological) in gynecological patients with Caprini score $\\ge$ 2 is still lacking. This study aims to evaluate the relative effectiveness of basic, mechanical, and pharmacological VTE prophylaxis strategies using a retrospective 1:3 matched nested case-control design. Furthermore, a decision tree model will be constructed to evaluate the incremental cost-effectiveness ratio (ICER) of these strategies to provide health economic evidence for optimizing VTE management pathways in gynecology

Detailed description

This is a two-phase study. Phase I is a retrospective nested case-control study. Patients undergoing gynecological surgery between Jan 2021 and Sep 2025 with a Caprini score $\\ge$ 2 will be screened. Case group includes patients who developed objectively confirmed symptomatic VTE postoperatively. Control group will be matched at a 1:3 ratio based on age ($\\pm$ 5 years), Body Mass Index (BMI), surgical approach, and benign/malignant nature of the disease. Conditional logistic regression will be used to calculate the adjusted Odds Ratios (ORs) for mechanical and pharmacological prophylaxis compared to basic prevention. In addition, uterus/myoma size and weight will be explored as potential gynecological-specific risk factors. Phase II involves health economic modeling. A decision tree model will be built utilizing the ORs obtained from Phase I, combined with real-world cost data (prophylaxis costs, VTE treatment costs, bleeding management costs) and baseline incidence rates from literature. The Incremental Cost-Effectiveness Ratio (ICER) will be calculated to determine the most cost-effective VTE prevention strategy at different Caprini risk thresholds

Interventions

None listed

Sponsors

Affiliated Hospital of Nantong University
Lead SponsorOTHER
Nantong No. 1 People's Hospital
CollaboratorUNKNOWN
The Affiliated Tumor Hospital of Nantong University, Nantong, Jiangsu Province, China
CollaboratorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Female patients aged $\\ge$ 18 years. Underwent inpatient gynecological surgery (benign or malignant indications). Postoperative Caprini risk score $\\ge$ 2. Complete medical and billing records available in the hospital information system.

Exclusion criteria

* Diagnosis of VTE prior to the current surgery. Currently receiving therapeutic anticoagulation for other medical conditions (e.g., atrial fibrillation, mechanical heart valves). Inferior vena cava filter placement prior to surgery. Incomplete key clinical or financial data.

Design outcomes

Primary

MeasureTime frame
Adjusted Odds Ratio (OR) of Symptomatic VTEUp to 30 days postoperatively.

Secondary

MeasureTime frame
Incremental Cost-Effectiveness Ratio (ICER)1 year
Incidence of Postoperative Bleeding ComplicationsUp to 30 days postoperatively
Association of Uterus/Myoma Weight with VTE RiskUp to 30 days postoperatively

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 7, 2026